Log In
Print
BCIQ
Print
Print this Print this
 

MEDI0680 (formerly AMP-514)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
Description mAb against programmed cell death 1 (PDCD1; PD-1; CD279)
Molecular Target Programmed cell death 1 (PD-1) (PDCD1) (CD279)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$500.0M

$225.0M

$275.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today